Abstract

The treatment of advanced non-small cell lung cancer (NSCLC) is currently driven by the detection of targetable oncogenic drivers, i.e. epidermal growth factor receptor, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, etc. Those patients who are wildtype for known and valuable oncogenes can receive standard chemotherapy as first-line treatment, with the possibility of adding bevacizumab. With regard to second-line treatment, nintedanib can improve the efficacy of docetaxel. Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors. The usefulness of nintedanib as an anticancer agent for NSCLC has been proved by both preclinical and clinical phase I and II trials; however, its approval for the use in clinical practice has been possible because of the positive results of the LUME-Lung 1 trial (nintedanib + docetaxel versus docetaxel alone) in terms of progression-free survival and overall survival, and a manageable tolerability profile. Therefore, the good results seen in the clinical trials with nintedanib in the second-line setting for NSCLC patients with adenocarcinoma subtype are encouraging enough to recommend it in clinical practice.
Lingua originaleEnglish
pagine (da-a)188-197
Numero di pagine10
RivistaTherapeutic Advances in Medical Oncology
Volume8
Stato di pubblicazionePublished - 2016

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Therapeutics
Phase II Clinical Trials
Clinical Trials, Phase I
Oncogenes
Epidermal Growth Factor Receptor
Antineoplastic Agents
Protein-Tyrosine Kinases
Disease-Free Survival
Adenocarcinoma
nintedanib
Clinical Trials
Drug Therapy
Lung
Survival

All Science Journal Classification (ASJC) codes

  • Oncology

Cita questo

@article{833f500e7ab8412ea365709b65e67daf,
title = "Nintedanib in NSCLC: Evidence to date and place in therapy",
abstract = "The treatment of advanced non-small cell lung cancer (NSCLC) is currently driven by the detection of targetable oncogenic drivers, i.e. epidermal growth factor receptor, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, etc. Those patients who are wildtype for known and valuable oncogenes can receive standard chemotherapy as first-line treatment, with the possibility of adding bevacizumab. With regard to second-line treatment, nintedanib can improve the efficacy of docetaxel. Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors. The usefulness of nintedanib as an anticancer agent for NSCLC has been proved by both preclinical and clinical phase I and II trials; however, its approval for the use in clinical practice has been possible because of the positive results of the LUME-Lung 1 trial (nintedanib + docetaxel versus docetaxel alone) in terms of progression-free survival and overall survival, and a manageable tolerability profile. Therefore, the good results seen in the clinical trials with nintedanib in the second-line setting for NSCLC patients with adenocarcinoma subtype are encouraging enough to recommend it in clinical practice.",
keywords = "FGFR, NSCLC, Oncology, PDGFR, VEGFR, angiogenesis, nintedanib, targeted therapy",
author = "Nadia Barraco and Giuseppe Bronte and Eugenio Fiorentino and Antonio Galvano and Marta Castiglia and Francesco Passiglia and Angela Listi' and Antonio Russo and Viviana Bazan and Sergio Rizzo",
year = "2016",
language = "English",
volume = "8",
pages = "188--197",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Nintedanib in NSCLC: Evidence to date and place in therapy

AU - Barraco, Nadia

AU - Bronte, Giuseppe

AU - Fiorentino, Eugenio

AU - Galvano, Antonio

AU - Castiglia, Marta

AU - Passiglia, Francesco

AU - Listi', Angela

AU - Russo, Antonio

AU - Bazan, Viviana

AU - Rizzo, Sergio

PY - 2016

Y1 - 2016

N2 - The treatment of advanced non-small cell lung cancer (NSCLC) is currently driven by the detection of targetable oncogenic drivers, i.e. epidermal growth factor receptor, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, etc. Those patients who are wildtype for known and valuable oncogenes can receive standard chemotherapy as first-line treatment, with the possibility of adding bevacizumab. With regard to second-line treatment, nintedanib can improve the efficacy of docetaxel. Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors. The usefulness of nintedanib as an anticancer agent for NSCLC has been proved by both preclinical and clinical phase I and II trials; however, its approval for the use in clinical practice has been possible because of the positive results of the LUME-Lung 1 trial (nintedanib + docetaxel versus docetaxel alone) in terms of progression-free survival and overall survival, and a manageable tolerability profile. Therefore, the good results seen in the clinical trials with nintedanib in the second-line setting for NSCLC patients with adenocarcinoma subtype are encouraging enough to recommend it in clinical practice.

AB - The treatment of advanced non-small cell lung cancer (NSCLC) is currently driven by the detection of targetable oncogenic drivers, i.e. epidermal growth factor receptor, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, etc. Those patients who are wildtype for known and valuable oncogenes can receive standard chemotherapy as first-line treatment, with the possibility of adding bevacizumab. With regard to second-line treatment, nintedanib can improve the efficacy of docetaxel. Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors. The usefulness of nintedanib as an anticancer agent for NSCLC has been proved by both preclinical and clinical phase I and II trials; however, its approval for the use in clinical practice has been possible because of the positive results of the LUME-Lung 1 trial (nintedanib + docetaxel versus docetaxel alone) in terms of progression-free survival and overall survival, and a manageable tolerability profile. Therefore, the good results seen in the clinical trials with nintedanib in the second-line setting for NSCLC patients with adenocarcinoma subtype are encouraging enough to recommend it in clinical practice.

KW - FGFR

KW - NSCLC

KW - Oncology

KW - PDGFR

KW - VEGFR

KW - angiogenesis

KW - nintedanib

KW - targeted therapy

UR - http://hdl.handle.net/10447/193809

UR - http://tam.sagepub.com/content/by/year

M3 - Article

VL - 8

SP - 188

EP - 197

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

ER -